Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy

Leukemia Research

Volumn 39, Issue 2, 2015, Pages 151-156

  Chen, Tzu Ting ^a   Chiu, Chang Fang ^a,b   Yang, Tse Yen ^a,c   Lin, Ching Chan ^a   Sargeant, Aaron M ^d   Yeh, Su Peng ^a,b   Liao, Yu Min ^a   Bai, Li Yuan ^a,b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d CHARLES RIVER LABORATORIES   (United States)

Author keywords

Chemotherapy; Diffuse large B cell lymphoma; Hepatitis C virus; Prognosis; Rituximab

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; METHYLPREDNISOLONE; OXALIPLATIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LARGE CELL LYMPHOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; THERAPY DELAY; AGED; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MORTALITY; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HEPATITIS C; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 84921439011     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.11.015     Document Type: Article

References (21)

1. Schollkopf C., Smedby K.E., Hjalgrim H., Rostgaard K., Panum I., Vinner L., et al. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 2008, 122:1885-1890.
2. de Sanjose S., Benavente Y., Vajdic C.M., Engels E.A., Morton L.M., Bracci P.M., et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008, 6:451-458.
3. Hartridge-Lambert S.K., Stein E.M., Markowitz A.J., Portlock C.S. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology 2012, 55:634-641.
4. Mele A., Pulsoni A., Bianco E., Musto P., Szklo A., Sanpaolo M.G., et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003, 102:996-999.
5. Matsuo K., Kusano A., Sugumar A., Nakamura S., Tajima K., Mueller N.E. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004, 95:745-752.
6. Kasama Y., Mizukami T., Kusunoki H., Peveling-Oberhag J., Nishito Y., Ozawa M., et al. B-cell-intrinsic hepatitis C virus expression leads to B-cell-lymphomagenesis and induction of NF-kappaB signalling. PLoS ONE 2014, 9:e91373.
7. Arcaini L., Merli M., Passamonti F., Bruno R., Brusamolino E., Sacchi P., et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol 2010, 85:46-50.
8. Besson C., Canioni D., Lepage E., Pol S., Morel P., Lederlin P., et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol 2006, 24:953-960.
9. Ennishi D., Maeda Y., Niitsu N., Kojima M., Izutsu K., Takizawa J., et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010, 116:5119-5125.
10. Nishikawa H., Tsudo M., Osaki Y. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience. Oncol Rep 2012, 28:835-840.
11. Sun C.A., Chen H.C., Lu C.F., You S.L., Mau Y.C., Ho M.S., et al. Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey. J Med Virol 1999, 59:290-296.
12. Sievert W., Altraif I., Razavi H.A., Abdo A., Ahmed E.A., Alomair A., et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011, 31(Suppl. 2):61-80.
13. Lake-Bakaar G., Dustin L., McKeating J., Newton K., Freeman V., Frost S.D. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 2007, 109:845-846.
14. Zaky A.H., Bakry R., El-Sayed M.I., Elwanis M.A., Nabih O. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era. Hematology 2014, 19:412-416.
15. Zuckerman E., Zuckerman T., Douer D., Qian D., Levine A.M. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998, 83:1224-1230.
16. Rosen H.R. Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest 2013, 123:4121-4130.
17. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009, 119:1746-1754.
18. Irshad M., Mankotia D.S., Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol 2013, 19:7896-7909.
19. Schoggins J.W., Rice C.M. Innate immune responses to hepatitis C virus. Curr Top Microbiol Immunol 2013, 369:219-242.
20. Huang Y.H., Hsiao L.T., Hong Y.C., Chiou T.J., Yu Y.B., Gau J.P., et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013, 31:2765-2772.
21. Hsu C., Tsou H.H., Lin S.J., Wang M.C., Yao M., Hwang W.L., et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2014, 59:2092-2100.